Bioregulator ResearchRead More →
Vilon Research
An evidence-led look at Vilon research: how independent the literature is, animal findings including an adverse one, and a computational DNA mechanism.
Dr. Tharindunee Jayakody
August 27, 2026
Bioregulator Research
Bronchogen Research
Dr. Tharindunee JayakodyPhDPublished 27 August 2026
Bronchogen is a short synthetic peptide, one of a set of compounds marketed as "peptide bioregulators" and developed at the St Petersburg Institute of Bioregulation and Gerontology. This page sets out what the published literature does and does not show.
Conflict of interest is a recurring theme in this literature, and it is set out below. Research-grade Bronchogen is supplied for laboratory research use only.
Identity, and a sequence that is not settled
Bronchogen is a tetrapeptide, four amino acids long, and its sequence is reported two different ways in the peer-reviewed record.
Three papers give it as Ala-Glu-Asp-Leu, written AEDL [1][2][3], and two others give it as Ala-Asp-Glu-Leu, written ADEL [4][5]. Vladimir Khavinson, who founded the originating institute, is a co-author on papers using both spellings.
The PubChem record carrying the name Bronchogen is CID 11690869, CAS 857267-12-0. Its molecular formula, C18H30N4O9, cannot decide between the two spellings, because AEDL and ADEL are sequence isomers built from the same four residues and share it exactly. The record's IUPAC name does discriminate, since it spells the residue order out as 2-aminopropanoyl (alanine), 4-carboxybutanoyl (glutamate), 3-carboxypropanoyl (aspartate), then 4-methylpentanoic acid (leucine). That is AEDL. It is a database curator's assignment rather than an experimental determination.
This is more than a spelling quibble, because the central claim made for these peptides is that residue order determines which DNA sequence a peptide recognizes. The direct DNA work is itself split across both spellings. The two most detailed biophysical studies of Bronchogen were run on the ADEL form [4][5], while an earlier fluorescence-quenching study assayed the AEDL form against DNA and deoxyribooligonucleotides [2]. No published paper resolves which sequence is correct.
Bronchogen also sits inside a nested series, and a 2022 review from the originating institute lists it beside a tripeptide differing by a single N-terminal alanine [11]. That sibling's name-to-sequence mapping rests on a single table in that review, so it should not be treated as settled either. No published study compares the two directly, so the literature offers no basis for saying what functionally separates them. On that point it is simply silent.
One research group produced nearly all of this
A PubMed search under the name returned twelve records in August 2026, several of them unrelated surgical papers about bronchogenic cysts and carcinoma. Of the records that genuinely concern the peptide, five of seven come from the originating institute's network.
That institute developed, patented and sells these compounds, and its founder is a named co-inventor on granted patents covering peptides in this family. Papers from the group nonetheless declare no conflict of interest, including a 2020 editorial in which each author declares no "patent/licensing arrangement" [14].
This does not make the findings wrong, but it does mean the field has not been independently established. A reader should weigh it on that basis.
What has been tested in cells (in vitro)
The DNA work is all in vitro. Differential scanning calorimetry with calf thymus and mouse liver DNA showed that the ADEL form raises the melting temperature of DNA [4]. The authors concluded the peptide "is not an adenine-thymine-specific or guanine-cytosine-specific ligand," and called the binding "strong and occasional" [4]. That is a finding against sequence specificity, reported by the originating group's own collaborators.
A 2014 study in Lung used spectrophotometry, viscometry and circular dichroism, and reported binding in the DNA major groove at N7 of guanine [5]. The same paper measured gene and protein expression in cultured human embryonic bronchial epithelial cells. None of those methods yields a binding constant, and none can establish sequence specificity on its own.
A third result points somewhere else again. A 2011 fluorescence-quenching study of the AEDL form reported preferential binding to deoxyribooligonucleotides carrying CNG sequences, and to CTG-containing sequences in particular [2]. Sequence preference of that kind is precisely what the calorimetry study found no evidence for, so these three DNA results are mutually incompatible rather than merely different.
A separate in vitro study reported that AEDL binds plant histones [6]. If these peptides act on histones, an expression change need not involve direct DNA contact at all. That is a second class of mechanism set against the direct-binding account, and it does nothing to resolve the conflict inside that account.
A cell-culture study of DNA methylation reported a mixed result honestly. AEDL changed methylation in step with expression at NKX2-1 and SCGB1A1, but at FOXA1, SCGB3A2 and SFTPA1 expression changed with no matching methylation change [7].
Bronchogen was also tested on organotypic explants from rat heart, lung, prostate and pancreas, alongside three sibling peptides [8]. A stimulating effect was reported at one concentration only, with no dose-response and no blinding described in the abstract.
Bronchogen in animal studies
Two rat studies are the strongest compound-specific evidence Bronchogen has. Both come from the Research Institute of Pulmonology at Pavlov First St Petersburg State Medical University, and neither carries a Khavinson-network author [9][10].
Rats were exposed to nitrogen dioxide for sixty days, a model of chronic obstructive pulmonary disease. Bronchogen was reported to remove signs of airway remodeling, including goblet cell hyperplasia, squamous metaplasia and emphysema, and secretory IgA production increased [9]. A 2017 Russian-language paper from the same group used the same model [10].
These are animal findings and should not be read as applying to people. They have not been replicated outside Russia, and rodent models of chronic obstructive pulmonary disease translate poorly to human disease. The authors sit at a different institution from the originating institute, though in the same city and publishing ecosystem.
What has not been studied
There is no clinical study of Bronchogen in people. The only human material anywhere in its literature is cultured bronchial epithelial cells, described as embryonic where the papers specify [1][5][7]. All three of those in vitro papers come from the originating institute's network.
There is no human pharmacokinetic data for Bronchogen, and no study has measured whether it survives digestion or reaches the bloodstream intact.
PepT1, the intestinal transporter that carries small peptides across the gut wall, handles di- and tripeptides only [13]. Bronchogen is a tetrapeptide, so it has no known carrier-mediated route across the intestinal wall. That is not the same as saying it cannot be absorbed, because the size argument does not rule out paracellular flux or other routes. The point is a mechanistic inference rather than an experiment, and nobody has tested Bronchogen as a PepT1 substrate.
The originating group has published an argument on the other side of this. A 2023 paper screened 26 ultrashort peptides, Bronchogen among them, and concluded that the LAT and PEPT transporters could carry them into cells [12]. That conclusion rests on molecular docking scores. No transport assay, uptake measurement or transporter-knockout control is reported in that work, so cell entry has been modeled rather than measured. A 2022 paper from the same group makes the same kind of modeling argument [11].
There is no lifespan or longevity study of Bronchogen in any species. A ClinicalTrials.gov search on 27 August 2026 returned a single hit, an unrelated airway gene-expression study, so no registered trial of this compound exists.
No formal toxicology package has been published for Bronchogen, and absence of published toxicology is not evidence of safety.
Frequently Asked Questions
Is there any human data on Bronchogen?
There is no clinical study of Bronchogen in people. The only human material in its literature is cultured bronchial epithelial cells, used in three in vitro papers from the originating institute's network [1][5][7]. A ClinicalTrials.gov search on 27 August 2026 returned only an unrelated airway gene-expression study, so no registered trial exists.
What is Bronchogen's actual amino acid sequence?
The sequence is contested: three papers report AEDL, Ala-Glu-Asp-Leu [1][2][3], and two report ADEL, Ala-Asp-Glu-Leu [4][5]. The two forms are sequence isomers, so their shared molecular formula cannot separate them, but the PubChem record's IUPAC name spells the residue order out as AEDL. Direct DNA-binding work has been published on both forms [2][4][5], and no paper resolves the discrepancy.
Has any of this been replicated by other groups?
Nothing in this literature has been replicated by an outside group. Two rat studies of a nitrogen dioxide lung model come from Pavlov First St Petersburg State Medical University and carry no Khavinson-network author [9][10]. That is original work at a second institution rather than a replication of anything. Of the PubMed records that genuinely concern this peptide, five of seven come from the originating institute's network, so the field has not been independently established.
How does Bronchogen differ from the shorter peptide it contains?
The published literature does not say. A 2022 review from the originating institute lists Bronchogen beside a tripeptide differing by one N-terminal alanine [11], but no study compares them directly. On the functional difference between them the literature is silent.
References
- 1Khavinson VKh, et al. Bulletin of Experimental Biology and Medicine. 2012. PMID 22808515. DOI: 10.1007/s10517-012-1664-1.
- 4Monaselidze JR, et al. Bulletin of Experimental Biology and Medicine. 2011. PMID 21240358. DOI: 10.1007/s10517-011-1146-x.
- 8Zakutskii AN, et al. Advances in Gerontology (Uspekhi Gerontologii). 2006. PMID 17152728. Russian language, English abstract.
- 9Kuzubova NA, et al. Bulletin of Experimental Biology and Medicine. 2015. PMID 26468022. DOI: 10.1007/s10517-015-3047-x.
- 10Titova ON, et al. Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova. 2017. PMID 30199201. Russian language, English abstract.
- 11Khavinson V, et al. International Journal of Molecular Sciences. 2022. PMID 35887081. DOI: 10.3390/ijms23147733. Review, with in silico docking tables.
- 12Khavinson VK, et al. Biomolecules. 2023. PMID 36979488. DOI: 10.3390/biom13030552. In silico docking study.
- 14Khavinson V, Popovich I, Mikhailova O. Acta Biomedica. 2020. PMID 32921699. DOI: 10.23750/abm.v91i3.10079. Editorial.
Reviewed & approved for scientific accuracy
Dr. Tharindunee Jayakody
PhD — Scientific Contributor and Reviewer
Dr Jayakody is a molecular pharmacologist with over 15 years of experience in translating complex research into clear, evidence-based explanations, with expertise on peptide therapeutics and other emerging compounds, particularly in delineating the mechanisms of action of therapeutics. As a contributor to research-focused platforms, Dr Jayakody aims to give scientifically literate readers a balanced view of what current data can and cannot support, helping them understand how promising findings in the lab translate, or sometimes fail to translate, into real-world applications.
View team profile →Related Articles
Bioregulator ResearchRead More →
Vesugen Research
An evidence-led look at Vesugen research: identity and naming, its presence inside four other products, and two uncontrolled human reports.
Dr. Tharindunee Jayakody
August 27, 2026
Bioregulator ResearchRead More →
Thymalin Research
An evidence-led look at Thymalin research: what the preparation actually is, the COVID-19 trial, the older human literature, and what is unproven.
Dr. Tharindunee Jayakody
August 27, 2026